Carmell Enters Securities Purchase Agreement With New And Existing Investors For The Issuance And Sale Of 8,065,210 Shares Of Its Common Stock And An Equal Number Of 5-Year Warrants, Both Priced At $0.23 Per Share, In A Private Placement For Aggregate...
Carmell Enters Securities Purchase Agreement With New And Existing Investors For The Issuance And Sale Of 8,065,210 Shares Of Its Common Stock And An Equal Number Of 5-Year Warrants, Both Priced At $0.23 Per Share, In A Private Placement For Aggregate...
Carmell Enters Securities Purchase Agreement With New And Existing Investors For The Issuance And Sale Of 8,065,210 Shares Of Its Common Stock And An Equal Number Of 5-Year Warrants, Both Priced At $0.23 Per Share, In A Private Placement For Aggregate Gross Proceeds Of $1.85M
Carmell與新老投資者簽署證券購買協議,發行並出售8,065,210股普通股和相等數量的5年期Warrants,價格均爲每股0.23美元,定向增發的總收益爲185萬美元。
Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of 8,065,210 shares of its common stock and an equal number of five-year warrants, both priced at $0.23 per share, in a private placement for aggregate gross proceeds of $1.85 million before deducting offering expenses and fees (the "Private Placement"). The warrants, if exercised, will result in an additional $1.85 million in proceeds to Carmell. The Private Placement was priced at a slight premium to the CTCX closing price on December 23, 2024.
Carmell Corporation(納斯達克:CTCX),一家專注於皮膚和頭髮健康的生物美學公司("Carmell"、"公司"、"我們"、"我們的"或"我們"),今天宣佈與新老投資者簽署了證券購買協議,發行並出售8,065,210股普通股和相等數量的五年期Warrants,價格均爲每股0.23美元,定向增發的總收益爲185萬美元,未扣除發行費用和費用("定向增發")。如果Warrants被行使,將給Carmell帶來額外的185萬美元收益。定向增發的價格略高於2024年12月23日CTCX的收盤價。
Said Mr. Rajiv Shukla, Chairman of Carmell, "We are happy to announce an additional round of investment from existing and new investors to support the continued commercial build out of our revolutionary bio-aesthetics product pipeline."
Carmell董事長Rajiv Shukla先生表示:"我們很高興宣佈來自現有和新投資者的額外投資,以支持我們革命性生物美學產品管道的持續商業發展。"
譯文內容由第三人軟體翻譯。